Fred Hutch Cancer Center | Strategic Alliance Partners

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

MB-106, a first-in-class, CD20-targeted autologous CAR T-cell therapy, led to durable clinical responses with low-grade cytokine release syndrome in patients with indolent lymphoma.

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.

Hiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

Anna B. Halpern, MD, discusses symptom control, transfusion independence, and spleen volume findings with the JAK and ACVR1 inhibitor momelotinib vs the JAK inhibitor ruxolitinib and danazol in patients with myelofibrosis with anemia.

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.